表紙
市場調査レポート

世界のポイントオブケア(POC)診断市場の将来展望

Global Point-of-Care Diagnostics Market Outlook 2020

発行 RNCOS E-Services Pvt. Ltd. 商品コード 304704
出版日 ページ情報 英文 75 Pages
即納可能
価格
本日の銀行送金レート: 1USD=106.02円で換算しております。
Back to Top
世界のポイントオブケア(POC)診断市場の将来展望 Global Point-of-Care Diagnostics Market Outlook 2020
出版日: 2015年05月01日 ページ情報: 英文 75 Pages
概要

ポイントオブケア(Point of Care:以下POC)検査とは、患者が開業医や救急車、自宅、屋外、病院などの様々な場所で診断を受けられる検査技術のことです。検査結果がその場で得られ、救急治療が可能となる結果、医療サービスの大幅改善につながります。各種技術(マイクロフルイディクス、デジタル光学技術、ラブ・オン・チップなど)の開発・改良に伴い、全世界のPOC検査(POCT)市場は2020年には300億米ドルの規模に達すると予想されています。市場の45%を米国が占め、ついで欧州・日本の順となっています。先進国では携帯型の検査装置の開発や、生活慣習病の有病者数増加などが市場成長を促進する一方、リソースの制約が厳しいところでも診断可能だという特徴が、新興国での市場促進につながっています。

当レポートでは、全世界のポイントオブケア(POC)診断の関連市場について分析し、技術の概要や今後の技術開発の見通し、世界各地域・主要国での今後の市場機会、主要企業のプロファイルといった情報をお届けいたします。

第1章 アナリストの見解

第2章 分析手法

第3章 体外診断市場の概要

  • イントロダクション
  • 体外(IV)診断とは何か?
  • 市場規模と成長率

第4章 POC(ポイントオブケア)診断市場の将来展望

第5章 市場区分

  • アプリケーション別
  • 地域別

第6章 市場成長促進因子および課題

  • 成長促進因子
  • 課題

第7章 業界の傾向と発展

  • 携帯型超音波装置が医療現場で活躍
  • POCT業界に押し寄せるマイクロ流体工学技術

第8章 競争環境

  • 大手企業の市場シェア
  • 主要企業
    • Roche Holding Ltd.
    • Abbott Laboratories
    • Johnson and Johnson
    • Alere
    • Medtronic
    • Bayer HealthCare
    • Siemens HealthCare
    • Beckman Coulter
    • Bio-Rad
    • Becton Dickinson

第9章 将来の展望と市場機会

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次

It is widely accepted that disease prevention and risk-reduction strategies have the potential to lower disease burden as well as improve the overall health of individuals. POCT technology offers such potential for diagnosis and treatment of patients, as it facilitates rapid availability of test results and hence, early clinical decision making and intervention.

Amidst a rising disease incidence, reduced budget, growing focus towards personalization of care, and ever-increasing integration of technology into healthcare, the global POCT market is expected to grow to almost US$ 30 Billion by 2020. In the "Global Point-of-Care Diagnostics Market Outlook 2020" report, the global POCT industry has been shown at a very crucial stage with POCT expanding into diverse disease areas, such as cancer and HIV diagnostics. The coming years will witness POCT take over routine diagnostics as focus would shift from 'curative' onto 'preventive care with enhanced patient involvement.'

Currently, the United States accounts for almost 45% of the total POCT market, followed by regions, such as Europe and Japan. In these developed regions, the proliferation of transportable, portable and handheld instruments along with ever-increasing incidence of lifestyle related disorders, such as diabetes has supported the growth of Point of Care testing. At the same time, rapid advancements in technology and infrastructure and the availability of diagnostic systems that cannot be employed in resource limited settings is expected to result in enhanced uptake of POCT in emerging nations. Countries such as Japan, China, India, Brazil and Mexico are expected to evolve as hot spots for development of the POCT technology in future.

The report provides a brief outlook of the IVD industry, covering major aspects, such as current market size, future growth, and current and future geographical segmentation. It also talks about the major players of IVD industry and their respective contribution to the current market.

The report then moves on to the global POCT industry, its current market size and future forecasts. Markets for major application segments such as glucose testing, blood chemistry etc. have also been discussed. Trends such as advanced micro fluidics, lab-on-a-chip assays as well as portable technologies have been elaborated. At the end, major players of the industry have been highlighted and a thorough profiling has been carried out to present the POCT product portfolios, business segmentations, strengths and weakness, and recent developments of every player.

Table of Contents

1. Analyst View

2. Research Methodology

3. In Vitro Diagnostic Market Overview

  • 3.1 Introduction
  • 3.2 What is In Vitro Diagnostics?
  • 3.3 Market Size and Growth

4. Point-of-Care Diagnostics Market Outlook 2020

5. Market Segmentation

  • 5.1 By Application
  • 5.2 By Geography

6. Market Drivers and Challenges

  • 6.1 Drivers
  • 6.2 Challenges

7. Industry Trends and Developments

  • 7.1 Portable Ultrasound Providing Care on Site
  • 7.2 Microfluidics Technology Crowding the POCT Industry

8. Competitive Landscape

  • 8.1 Market Share of Major Players
  • 8.2 Key Players
    • 8.2.1 Roche Holding Ltd.
    • 8.2.2 Abbott Laboratories
    • 8.2.3 Johnson and Johnson
    • 8.2.4 Alere
    • 8.2.5 Medtronic
    • 8.2.6 Bayer HealthCare
    • 8.2.7 Siemens HealthCare
    • 8.2.8 Beckman Coulter
    • 8.2.9 Bio-Rad
    • 8.2.10 Becton Dickinson

9. Future Outlook/Market Opportunities

List of Figures:

  • Figure 3-1: Global - Diabetes Incidence (Million), 2014 & 2035
  • Figure 3-2: Global - In Vitro Diagnostic Market (Billion US$), 2014-2020
  • Figure 3-3: Global - In Vitro Diagnostic Market by Region (%), 2014
  • Figure 3-4: Global - In Vitro Diagnostic Market by Region (%), 2020
  • Figure 3-5: Global - In Vitro Diagnostic Market by Players (%), 2014
  • Figure 4-1: Global - Share of POCT in the IVD Market (%), 2014 & 2020
  • Figure 4-2: Global - Point of Care Testing Market (Billion US$), 2014-2020
  • Figure 5-1: Global - Point of Care Testing Market by Application (%), 2014
  • Figure 5-2: Global - Point of Care Testing Market by Application (%), 2020
  • Figure 5-3: Global - Point of Care Testing Market by Players (%), 2014
  • Figure 8-1: Global - Point-of-Care Testing Market by Players (%), 2014
  • Figure 8-2: Roche Holdings Ltd - Revenue by Business Segment (%), 2014
  • Figure 8-3: Abbott Laboratories - Revenue by Business Segment (%), 2014
  • Figure 8-4: Abbott Laboratories - Revenue by Region (%), 2014
  • Figure 8-5: Johnson & Johnson - Revenue by Business Segment (%), 2014
  • Figure 8-6: Johnson & Johnson - Medical Devices and Dx Revenue by Segment (%), 2014
  • Figure 8-7: Johnson & Johnson - Revenue by Region (%), 2014
  • Figure 8-8: Johnson & Johnson - Medical Devices and Dx Revenue by Region (%), 2014
  • Figure 8-9: Alere Inc. - Revenue by Business Segment (%), 2013
  • Figure 8-10: Alere Inc. - Professional Diagnostic Division Revenue by Segment (%), 2013
  • Figure 8-11: Medtronic Inc. - Revenue by Business Segment (%), 2014
  • Figure 8-12: Medtronic Inc. - Revenue by Region (%), 2014
  • Figure 8-13: Bayer HealthCare - Revenue by Business Segment (%), 2014
  • Figure 8-14: Bayer HealthCare - Revenue by Business Region (%), 2014
  • Figure 8-15: Bayer HealthCare - Consumer Health Revenue by Segment (%), 2014
  • Figure 8-16: Siemens HealthCare - Revenue by Region (%), 2014
  • Figure 8-17: Siemens HealthCare - Revenue by Business Segment (%), 2014
  • Figure 8-18: Bio-Rad - Revenue by Segment (%), 2014
  • Figure 8-19: Bio-Rad - Revenue by Region (%), 2014
  • Figure 8-20: Becton Dickinson - Revenue by Business Segment (%), 2014
  • Figure 8-21: Becton Dickinson - Revenue by Region (%), 2014

List of Tables:

  • Table 8-1: Roche Holdings Ltd - POCT Product Portfolio
  • Table 8-2: Roche Holdings Ltd - Key POCT Product Launches for 2015
  • Table 8-3: Roche Holdings Ltd - Key Financials (Million CHF), 2012-2014
  • Table 8-4: Roche Holdings Ltd - Strengths and Weaknesses
  • Table 8-5: Abbott Laboratories - POCT Product Portfolio
  • Table 8-6: Abbott Laboratories - Key Financials (Million US$), 2012-2014
  • Table 8-7: Abbott Laboratories - Strengths and Weaknesses
  • Table 8-8: Johnson & Johnson - POCT Product Portfolio
  • Table 8-9: Johnson & Johnson - Key Financials (Million US$), 2012-2014
  • Table 8-10: Johnson & Johnson - Strengths and Weaknesses
  • Table 8-11: Alere Inc. - POCT Product Portfolio
  • Table 8-12: Alere Inc. - Key Financials (Million US$), 2011-2013
  • Table 8-13: Alere Inc. - Strengths and Weaknesses
  • Table 8-14: Medtronic Inc. - POCT Product Portfolio
  • Table 8-15: Medtronic Inc. - Key Financials (Million US$), 2012-2014
  • Table 8-16: Medtronic Inc. - Strengths and Weaknesses
  • Table 8-17: Bayer HealthCare - POCT Product Portfolio
  • Table 8-18: Bayer HealthCare - Key Financials (Million €), 2012-2014
  • Table 8-19: Bayer HealthCare - Strengths and Weaknesses
  • Table 8-20: Siemens Healthcare - POCT Product Portfolio
  • Table 8-21: Siemens Healthcare - Key Financials (Million €), 2012-2014
  • Table 8-22: Siemens Healthcare - Strength and Weaknesses
  • Table 8-23: Beckman Coulter - POCT Product Portfolio
  • Table 8-24: Beckman Coulter - Strengths and Weaknesses
  • Table 8-25: Bio-Rad - POCT Product Portfolio
  • Table 8-26: Bio-Rad - Key Financials (Million US$) 2012-2014
  • Table 8-27: Bio-Rad - Strengths and Weaknesses
  • Table 8-28: Becton Dickinson - POCT Product Portfolio
  • Table 8-29: Becton Dickinson - Key Financials (Million US$), 2012-2014
  • Table 8-30: Becton Dickinson - Strengths and Weaknesses
Back to Top